Nonlinear association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hyperuricemia in cancer patients: evidence from NHANES 2007-2018

• Published in: Lipids in health and disease Vol. 23; no. 1; pp. 269 - 12
• Main Authors: He, Ran, Zhu, Qilei, Ye, Youjun, Chen, Shuaihang, Xie, Changsheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.08.2024; BioMed Central; BMC
• Subjects: Adult; Aged; Cancer; Cancer patients; Cholesterol; Cholesterol, HDL - blood; Comparative analysis; Complications and side effects; Cross-sectional study; Female; Gout - blood; Gout - epidemiology; Health aspects; Humans; Hyperuricemia; Hyperuricemia - blood; Hyperuricemia - complications; Hyperuricemia - epidemiology; Logistic Models; Male; Medical research; Medicine, Experimental; Middle Aged; Neoplasms - blood; Neoplasms - complications; Neoplasms - epidemiology; NHANES; NHHR; Nutrition Surveys; Oncology, Experimental; Physiological aspects; Prevalence; Risk Factors; Uric Acid - blood; China; NHHR; Hyperuricemia; NHANES; Cross-sectional study; Cancer
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-024-02261-3

Evidence shows that cancer patients are more likely to have hyperuricemia (HUA) compared to the general population, with lipid metabolism playing a significant role. However, it is still unclear whether there is a non-linear relationship between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and HUA in these patients. This study aims to explore the association between NHHR and HUA in cancer patients. This study included participants from the NHANES database from 2007 to 2018. We used multivariable logistic regression, restricted cubic splines (RCS) analysis, and subgroup analysis to examine the association between NHHR and HUA and gout in cancer patients, as well as to investigate differences in this association among specific subgroups. A total of 2826 participants were included, with a HUA prevalence of 24.30%. Weighted multivariable logistic regression showed that for each unit increase in NHHR, the odds of HUA in cancer patients increased by 16% (95% confidence interval [CI]: 1.06, 1.29, P = 0.002). When NHHR was divided into tertiles, those in the highest tertile (Q3) had a 1.84 times higher odds of developing HUA compared to those in the lowest tertile (Q1) (95% CI: 1.32, 2.58, P < 0.001). However, there was no significant association with gout. RCS analysis further revealed a significant non-linear positive association, particularly among males. Subgroup analysis and interaction tests indicated a stronger association in cancer patients who did not have a history of stroke. There is a non-linear association between NHHR and HUA in cancer patients.